LifeSci Venture Partners
VC Fund
New York, United States
LifeSci Venture Partners is an early-stage investment firm that invests in early-stage life sciences and healthcare companies. The firm provides companies in the life sciences industry with comprehensive solutions to communications and investor outreach. Their investment principals have broad-ranging life sciences experience including public andprivate investing, deal structuring, investment banking, equity capital markets, equity research, and bench research both basic science and applied.
- Total investments:
- 43
- Last investment:
- Lead investor:
- 5%
- Fund size:
- $23M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries LifeSci Venture Partners invests in
Stages LifeSci Venture Partners invests in
Countries LifeSci Venture Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew A. Sauter
|
|||
Andrew McDonald
|
|||
Andrew McDonald
|
|||
Ira Kalfus
|
|||
Scott Janssen
|
Investment Focus
Industry
- Biotechnology 27 (63%)
- Health Care 17 (40%)
- Therapeutics 13 (30%)
- Pharmaceutical 11 (26%)
- Medical 9 (21%)
Stage
- Series B 14 (33%)
- Series C 10 (23%)
- Series A 9 (21%)
- Post-IPO Equity 4 (9%)
- Venture - Series Unknown 2 (5%)
Country
- United States 31 (72%)
- China 1 (2%)
- Israel 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrew A. Sauter
Consulting CFO
|
Consulting CFO | Total investments: 0 | Find email | |
|
Andrew McDonald
Founding Partner&CEO
|
Founding Partner&CEO | Total investments: 0 | Find email | |
|
Andrew McDonald
Founding Partner&CEO
|
Founding Partner&CEO | Total investments: 0 | Find email | |
|
Ira Kalfus
CMO
|
CMO | Total investments: 0 | Find email | |
|
Scott Janssen
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Quince Therapeutics
|
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M / Post-IPO Equity / May 18, 2026 | |
Achieve Life Science
|
Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M / Post-IPO Equity / Apr 16, 2026 | |
Yarrow
|
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease. | $200M / Venture - Series Unknown / Dec 17, 2025 | |
VeraDermics
|
Veradermics is a dermatology-focused biopharmaceutical company that develops treatments for common skin and hair conditions. Its lead drug candidate, VDPHL01, is an extended-release oral minoxidil being tested in Phase 3 clinical trials for pattern hair loss in both women and men. The company also has pipeline programs targeting conditions such ascommon warts, molluscum contagiosum, and atopic dermatitis. | $150M / Series C / Oct 16, 2025 | |
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series C / Mar 19, 2025 | |
Candid Therapeutics
|
Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $370M / Series A / Sep 09, 2024 | |
Averto Medical
|
Savage Medical manufactures devices for medical use, enabling patients to get solutions for gastrointestinal diseases. They offer solutions for patients suffering from gastrointestinal diseases. | $30M / Series A / May 07, 2024 | |
ProfoundBio
|
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. | $112M / Series B / Feb 13, 2024 | |
Beta Bionics
|
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in aready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States. | $100M / Series D / Aug 30, 2023 | |
MOMA Therapeutics
|
MOMA Therapeutics operates as a biotechnology company. MOMA Therapeutics discover the next generation of precision medicines by targeting the molecular machines that underlie human disease. | $150M / Series B / May 10, 2022 | |
| See all 43 investments → | |||
Co-Investors
Logos Capital
11 deals together
Janus Henderson Investors
10 deals together
Perceptive Advisors
9 deals together
Samsara BioCapital
9 deals together
Venrock Healthcare Capital Partners
9 deals together
RTW Investments
8 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does LifeSci Venture Partners invest in?
LifeSci Venture Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 43 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact LifeSci Venture Partners?
Public channels for LifeSci Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LifeSci Venture Partners?
The team at LifeSci Venture Partners includes Andrew A. Sauter (Consulting CFO), Andrew McDonald (Founding Partner&CEO) and Andrew McDonald (Founding Partner&CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
